Portal de Periódicos da CAPES

CANCER PROGRESSION AND SURVIVAL RATES FOLLOWING ANATOMICAL RADICAL RETROPUBIC PROSTATECTOMY IN 3,478 CONSECUTIVE PATIENTS: LONG-TERM RESULTS

2004; Lippincott Williams & Wilkins; Volume: 172; Issue: 3 Linguagem: Inglês

10.1097/01.ju.0000134888.22332.bb

1527-3792

Kimberly A. Roehl, Misop Han, Christian G. Ramos, Jo Ann V. Antenor, William J. Catàlona,

Prostate Cancer Treatment and Research

No AccessJournal of UrologyAdult Urology: Oncology: Prostate/Testis/Penis/Urethra1 Sep 2004CANCER PROGRESSION AND SURVIVAL RATES FOLLOWING ANATOMICAL RADICAL RETROPUBIC PROSTATECTOMY IN 3,478 CONSECUTIVE PATIENTS: LONG-TERM RESULTS KIMBERLY A. ROEHL, MISOP HAN, CHRISTIAN G. RAMOS, JO ANN V. ANTENOR, and WILLIAM J. CATALONA KIMBERLY A. ROEHLKIMBERLY A. ROEHL More articles by this author , MISOP HANMISOP HAN More articles by this author , CHRISTIAN G. RAMOSCHRISTIAN G. RAMOS More articles by this author , JO ANN V. ANTENORJO ANN V. ANTENOR More articles by this author , and WILLIAM J. CATALONAWILLIAM J. CATALONA More articles by this author View All Author Informationhttps://doi.org/10.1097/01.ju.0000134888.22332.bbAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: We updated a long-term cancer control outcome in a large anatomical radical retropubic prostatectomy (RRP) series. We also evaluated the perioperative parameters that predict cancer specific outcomes following surgery. Materials and Methods: From May 1983 to February 2003, 1 surgeon (WJC) performed RRP in 3,478 consecutive men. Patients were followed with semiannual serum prostate specific antigen (PSA) tests and annual digital rectal examinations. We used Kaplan-Meier product limit estimates to calculate actuarial 10-year probabilities of biochemical progression-free survival, cancer specific survival and overall survival. Multivariate Cox proportional hazards models were used to determine independent perioperative predictors of cancer progression. Results: At a mean followup of 65 months (range 0 to 233) actuarial 10-year biochemical progression-free, cancer specific and overall survival probabilities were 68%, 97% and 83%, respectively. On multivariate analysis biochemical progression-free survival probability was significantly associated with preoperative PSA, clinical tumor stage, Gleason sum, pathological stage and treatment era. Cancer specific survival and overall survival rates were also significantly associated with clinicopathological parameters. Conclusions: RRP can be performed with excellent survival outcomes. Favorable clinicopathological parameters and treatment in the PSA era are associated with improved cancer control. References 1 : Impotence following radical prostatectomy: insight into etiology and prevention. J Urol1982; 128: 492. Link, Google Scholar 2 : Potency, continence and complication rates in 1,870 consecutive radical retropubic prostatectomies. J Urol1999; 162: 433. Link, Google Scholar 3 : Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy.The 15-year Johns Hopkins experience. Urol Clin North Am2001; 28: 555. Google Scholar 4 : Prostate Cancer Trends 1973–1995. SEER Program, National Cancer Institute. Bethesda: National Cancer Institute1999. pub# 99-4543. Google Scholar 5 : Cancer recurrence and survival rates after anatomic radical retropubic prostatectomy for prostate cancer: intermediate-term results. J Urol1998; 160: 2428. Link, Google Scholar 6 : 5-Year tumor recurrence rates after anatomical radical retropubic prostatectomy for prostate cancer. J Urol1994; 152: 1837. Link, Google Scholar 7 : American Joint Committee on Cancer: Manual for Staging of Cancer. Philadelphia: J. B. Lippincott Co.1992: 181. Google Scholar 8 : Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol1974; 111: 58. Abstract, Google Scholar 9 : The incidence and significance of detectable levels of serum prostate specific antigen after radical prostatectomy. J Urol1994; 152: 1821. Link, Google Scholar 10 : Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer. J Urol1994; 152: 1850. Link, Google Scholar 11 : Natural history of progression after PSA elevation following radical prostatectomy. JAMA1999; 281: 1591. Google Scholar 12 : Era specific biochemical recurrence-free survival following radical prostatectomy for clinically localized prostate cancer. J Urol2001; 166: 416. Link, Google Scholar 13 : Cancer control with radical prostatectomy alone in 1,000 consecutive patients. J Urol2002; 167: 528. Link, Google Scholar 14 : Intermediate-term survival results in clinically understaged prostate cancer patients following radical prostatectomy. J Urol1988; 140: 540. Link, Google Scholar From the Departments of Psychiatry (KAR), Surgery/Urology (WJC) and Neurology (JAVA), School of Medicine, Washington University, St. Louis, Missouri, Department of Urology, Feinberg School of Medicine, Northwestern University (MH, WJC), Chicago, Illinois, and Clinica Las Condes (CGR), Santiago, Chile© 2004 by American Urological Association, Inc.FiguresReferencesRelatedDetailsCited byAndriole G, Kostakoglu L, Chau A, Duan F, Mahmood U, Mankoff D, Schuster D, Siegel B, Adler L, Belkoff L, Burzon D, Dato P, Farwell M, Fogelson S, Gardiner P, Hanna L, Hoffman J, Intenzo C, Josephson D, Kaminetsky J, Kipper M, Krynyckyi B, Linder K, Marques H, Melnick J, Miller M, Oh W, Philips S, Rose J, Savir-Baruch B, Stevens D, Tewari A, Twardowski P, Ward P, Wasserman M, Weick S and (Michael) Yu J (2019) The Impact of Positron Emission Tomography with 18F-Fluciclovine on the Treatment of Biochemical Recurrence of Prostate Cancer: Results from the LOCATE TrialJournal of Urology, VOL. 201, NO. 2, (322-331), Online publication date: 1-Feb-2019.Ravi P, Karnes R, Rangel L and Pagliaro L (2018) Outcomes and Prognostic Factors in Men Receiving Androgen Deprivation Therapy for Prostate Cancer Recurrence after Radical ProstatectomyJournal of Urology, VOL. 200, NO. 5, (1075-1081), Online publication date: 1-Nov-2018.Liesenfeld L, Kron M, Gschwend J and Herkommer K (2018) Prognostic Factors for Biochemical Recurrence More than 10 Years after Radical ProstatectomyJournal of Urology, VOL. 197, NO. 1, (143-148), Online publication date: 1-Jan-2017.Bach-Gansmo T, Nanni C, Nieh P, Zanoni L, Bogsrud T, Sletten H, Korsan K, Kieboom J, Tade F, Odewole O, Chau A, Ward P, Goodman M, Fanti S, Schuster D and Willoch F (2016) Multisite Experience of the Safety, Detection Rate and Diagnostic Performance of Fluciclovine (18F) Positron Emission Tomography/Computerized Tomography Imaging in the Staging of Biochemically Recurrent Prostate CancerJournal of Urology, VOL. 197, NO. 3 Part 1, (676-683), Online publication date: 1-Mar-2017.Robertson N, Sala E, Benz M, Landa J, Scardino P, Scher H, Hricak H and Vargas H (2018) Combined Whole Body and Multiparametric Prostate Magnetic Resonance Imaging as a 1-Step Approach to the Simultaneous Assessment of Local Recurrence and Metastatic Disease after Radical ProstatectomyJournal of Urology, VOL. 198, NO. 1, (65-70), Online publication date: 1-Jul-2017.Toussi A, Stewart-Merrill S, Boorjian S, Psutka S, Thompson R, Frank I, Tollefson M, Gettman M, Carlson R, Rangel L and Karnes R (2018) Standardizing the Definition of Biochemical Recurrence after Radical Prostatectomy—What Prostate Specific Antigen Cut Point Best Predicts a Durable Increase and Subsequent Systemic Progression?Journal of Urology, VOL. 195, NO. 6, (1754-1759), Online publication date: 1-Jun-2016.Uchida T, Tomonaga T, Kim H, Nakano M, Shoji S, Nagata Y and Terachi T (2018) Improved Outcomes with Advancements in High Intensity Focused Ultrasound Devices for the Treatment of Localized Prostate CancerJournal of Urology, VOL. 193, NO. 1, (103-110), Online publication date: 1-Jan-2015.Daniunaite K, Jarmalaite S, Kalinauskaite N, Petroska D, Laurinavicius A, Lazutka J and Jankevicius F (2018) Prognostic Value of RASSF1 Promoter Methylation in Prostate CancerJournal of Urology, VOL. 192, NO. 6, (1849-1855), Online publication date: 1-Dec-2014.Flanigan R, Polcari A, Shore N, Price T, Sims R, Maher J, Whitmore J and Corman J (2018) An Analysis of Leukapheresis and Central Venous Catheter Use in the Randomized, Placebo Controlled, Phase 3 IMPACT Trial of Sipuleucel-T for Metastatic Castrate Resistant Prostate CancerJournal of Urology, VOL. 189, NO. 2, (521-526), Online publication date: 1-Feb-2013.Mitchell C, Lowe V, Rangel L, Hung J, Kwon E and Karnes R (2018) Operational Characteristics of 11C-Choline Positron Emission Tomography/Computerized Tomography for Prostate Cancer with Biochemical Recurrence After Initial TreatmentJournal of Urology, VOL. 189, NO. 4, (1308-1313), Online publication date: 1-Apr-2013.Greene K, Albertsen P, Babaian R, Carter H, Gann P, Han M, Kuban D, Sartor A, Stanford J, Zietman A and Carroll P (2018) Prostate Specific Antigen Best Practice Statement: 2009 UpdateJournal of Urology, VOL. 189, NO. 1S, (S2-S11), Online publication date: 1-Jan-2013.Karnes R, Bergstralh E, Davicioni E, Ghadessi M, Buerki C, Mitra A, Crisan A, Erho N, Vergara I, Lam L, Carlson R, Thompson D, Haddad Z, Zimmermann B, Sierocinski T, Triche T, Kollmeyer T, Ballman K, Black P, Klee G and Jenkins R (2018) Validation of a Genomic Classifier that Predicts Metastasis Following Radical Prostatectomy in an At Risk Patient PopulationJournal of Urology, VOL. 190, NO. 6, (2047-2053), Online publication date: 1-Dec-2013.Spahn M, Briganti A, Capitanio U, Kneitz B, Gontero P, Karnes J, Schubert M, Montorsi F, Scholz C, Bader P, van Poppel H and Joniau S (2018) Outcome Predictors of Radical Prostatectomy Followed by Adjuvant Androgen Deprivation in Patients with Clinical High Risk Prostate Cancer and pT3 Surgical Margin Positive DiseaseJournal of Urology, VOL. 188, NO. 1, (84-90), Online publication date: 1-Jul-2012.Boorjian S, Tollefson M, Thompson R, Rangel L, Bergstralh E and Karnes R (2018) Natural History of Biochemical Recurrence After Radical Prostatectomy with Adjuvant Radiation TherapyJournal of Urology, VOL. 188, NO. 5, (1761-1766), Online publication date: 1-Nov-2012.Mullins J, Feng Z, Trock B, Epstein J, Walsh P and Loeb S (2018) The Impact of Anatomical Radical Retropubic Prostatectomy on Cancer Control: The 30-Year AnniversaryJournal of Urology, VOL. 188, NO. 6, (2219-2224), Online publication date: 1-Dec-2012.Wolin K, Luly J, Sutcliffe S, Andriole G and Kibel A (2018) Risk of Urinary Incontinence Following Prostatectomy: The Role of Physical Activity and ObesityJournal of Urology, VOL. 183, NO. 2, (629-633), Online publication date: 1-Feb-2010.Barocas D, Salem S, Kordan Y, Herrell S, Chang S, Clark P, Davis R, Baumgartner R, Phillips S, Cookson M and Smith J (2018) Robotic Assisted Laparoscopic Prostatectomy Versus Radical Retropubic Prostatectomy for Clinically Localized Prostate Cancer: Comparison of Short-Term Biochemical Recurrence-Free SurvivalJournal of Urology, VOL. 183, NO. 3, (990-996), Online publication date: 1-Mar-2010.Boorjian S, Karnes R, Crispen P, Carlson R, Rangel L, Bergstralh E and Blute M (2018) The Impact of Positive Surgical Margins on Mortality Following Radical Prostatectomy During the Prostate Specific Antigen EraJournal of Urology, VOL. 183, NO. 3, (1003-1009), Online publication date: 1-Mar-2010.Giovacchini G, Picchio M, Briganti A, Cozzarini C, Scattoni V, Salonia A, Landoni C, Gianolli L, Di Muzio N, Rigatti P, Montorsi F and Messa C (2018) [11C]Choline Positron Emission Tomography/Computerized Tomography to Restage Prostate Cancer Cases With Biochemical Failure After Radical Prostatectomy and No Disease Evidence on Conventional ImagingJournal of Urology, VOL. 184, NO. 3, (938-943), Online publication date: 1-Sep-2010.Weiss G, Cottrell S, Distler J, Schatz P, Kristiansen G, Ittmann M, Haefliger C, Lesche R, Hartmann A, Corman J and Wheeler T (2018) DNA Methylation of the PITX2 Gene Promoter Region is a Strong Independent Prognostic Marker of Biochemical Recurrence in Patients With Prostate Cancer After Radical ProstatectomyJournal of Urology, VOL. 181, NO. 4, (1678-1685), Online publication date: 1-Apr-2009.Greene K, Albertsen P, Babaian R, Carter H, Gann P, Han M, Kuban D, Sartor A, Stanford J, Zietman A and Carroll P (2018) Prostate Specific Antigen Best Practice Statement: 2009 UpdateJournal of Urology, VOL. 182, NO. 5, (2232-2241), Online publication date: 1-Nov-2009.Boorjian S, Karnes R, Crispen P, Rangel L, Bergstralh E and Blute M (2018) Radiation Therapy After Radical Prostatectomy: Impact on Metastasis and SurvivalJournal of Urology, VOL. 182, NO. 6, (2708-2715), Online publication date: 1-Dec-2009.Wagner M, Sokoloff M and Daneshmand S (2018) The Role of Pelvic Lymphadenectomy for Prostate Cancer—Therapeutic?Journal of Urology, VOL. 179, NO. 2, (408-413), Online publication date: 1-Feb-2008.Boorjian S, Karnes R, Rangel L, Bergstralh E and Blute M (2018) Mayo Clinic Validation of the D’Amico Risk Group Classification for Predicting Survival Following Radical ProstatectomyJournal of Urology, VOL. 179, NO. 4, (1354-1361), Online publication date: 1-Apr-2008.Sim H, Telesca D, Culp S, Ellis W, Lange P, True L and Lin D (2018) Tertiary Gleason Pattern 5 in Gleason 7 Prostate Cancer Predicts Pathological Stage and Biochemical RecurrenceJournal of Urology, VOL. 179, NO. 5, (1775-1779), Online publication date: 1-May-2008.Hamilton R, Aronson W, Terris M, Kane C, Presti J, Amling C and Freedland S (2018) Limitations of Prostate Specific Antigen Doubling Time Following Biochemical Recurrence After Radical Prostatectomy: Results From the SEARCH DatabaseJournal of Urology, VOL. 179, NO. 5, (1785-1790), Online publication date: 1-May-2008.Jayachandran J, Bañez L, Levy D, Aronson W, Terris M, Presti J, Amling C, Kane C and Freedland S (2018) Risk Stratification for Biochemical Recurrence in Men With Positive Surgical Margins or Extracapsular Disease After Radical Prostatectomy: Results From the SEARCH DatabaseJournal of Urology, VOL. 179, NO. 5, (1791-1796), Online publication date: 1-May-2008.Cottrell S, Jung K, Kristiansen G, Eltze E, Semjonow A, Ittmann M, Hartmann A, Stamey T, Haefliger C and Weiss G (2018) Discovery and Validation of 3 Novel DNA Methylation Markers of Prostate Cancer PrognosisJournal of Urology, VOL. 177, NO. 5, (1753-1758), Online publication date: 1-May-2007.Kibel A, Rosenbaum E, Kattan M, Picus J, Dreicer R, Klein E, Chatta G, Nelson J, DiPaola R, Roth B, Cookson M, Wilding G, Jarrard D, Beer T, Ryan C, Petrylak D, Benson M, Partin A, Garrett-Mayer E and Eisenberger M (2018) Adjuvant Weekly Docetaxel for Patients With High Risk Prostate Cancer After Radical Prostatectomy: A Multi-Institutional Pilot StudyJournal of Urology, VOL. 177, NO. 5, (1777-1781), Online publication date: 1-May-2007.Cooperberg M, Broering J, Kantoff P and Carroll P (2007) Contemporary Trends in Low Risk Prostate Cancer: Risk Assessment and TreatmentJournal of Urology, VOL. 178, NO. 3S, (S14-S19), Online publication date: 1-Sep-2007.Miller J, Smith A, Kouba E, Wallen E and Pruthi R (2018) Prospective Evaluation of Short-Term Impact and Recovery of Health Related Quality of Life in Men Undergoing Robotic Assisted Laparoscopic Radical Prostatectomy Versus Open Radical ProstatectomyJournal of Urology, VOL. 178, NO. 3, (854-859), Online publication date: 1-Sep-2007.Steuber T, Graefen M, Haese A, Erbersdobler A, Chun F, Schlom T, Perrotte P, Huland H and Karakiewicz P (2018) Validation of a Nomogram for Prediction of Side Specific Extracapsular Extension at Radical ProstatectomyJournal of Urology, VOL. 175, NO. 3, (939-944), Online publication date: 1-Mar-2006.Andrén O, Fall K, Franzén L, Andersson S, Johansson J and Rubin M (2018) How Well Does the Gleason Score Predict Prostate Cancer Death? A 20-Year Followup of a Population Based Cohort in SwedenJournal of Urology, VOL. 175, NO. 4, (1337-1340), Online publication date: 1-Apr-2006.Porter C, Kodama K, Gibbons R, Correa R, Chun F, Perrotte P and Karakiewicz P (2018) 25-Year Prostate Cancer Control and Survival Outcomes: A 40-Year Radical Prostatectomy Single Institution SeriesJournal of Urology, VOL. 176, NO. 2, (569-574), Online publication date: 1-Aug-2006.Buskirk S, Pisansky T, Schild S, Macdonald O, Wehle M, Kozelsky T, Collie A, Ferrigni R, Myers R, Prussak K, Heckman M, Crook J, Parker A and Igel T (2018) Salvage Radiotherapy for Isolated Prostate Specific Antigen Increase After Radical Prostatectomy: Evaluation of Prognostic Factors and Creation of a Prognostic Scoring SystemJournal of Urology, VOL. 176, NO. 3, (985-990), Online publication date: 1-Sep-2006.Eggener S, Roehl K, Yossepowitch O and Catalona W (2018) Prediagnosis Prostate Specific Antigen Velocity is Associated With Risk of Prostate Cancer Progression Following Brachytherapy and External Beam Radiation TherapyJournal of Urology, VOL. 176, NO. 4, (1399-1403), Online publication date: 1-Oct-2006.Montie J (2018) Initial Therapy With Radical Prostatectomy for High Risk Localized Prostate CancerJournal of Urology, VOL. 176, NO. 6S, (S27-S29), Online publication date: 1-Dec-2006.THOMPSON K, HERNÁNDEZ J, CANBY-HAGINO E, TROYER D and THOMPSON I (2018) PROGNOSTIC FEATURES IN MEN WHO DIED OF PROSTATE CANCERJournal of Urology, VOL. 174, NO. 2, (553-556), Online publication date: 1-Aug-2005.PAZONA J, HAN M, HAWKINS S, ROEHL K and CATALONA W (2018) SALVAGE RADIATION THERAPY FOR PROSTATE SPECIFIC ANTIGEN PROGRESSION FOLLOWING RADICAL PROSTATECTOMY: 10-YEAR OUTCOME ESTIMATESJournal of Urology, VOL. 174, NO. 4 Part 1, (1282-1286), Online publication date: 1-Oct-2005.MATTHEW A, GOLDMAN A, TRACHTENBERG J, ROBINSON J, HORSBURGH S, CURRIE K and RITVO P (2018) SEXUAL DYSFUNCTION AFTER RADICAL PROSTATECTOMY: PREVALENCE, TREATMENTS, RESTRICTED USE OF TREATMENTS AND DISTRESSJournal of Urology, VOL. 174, NO. 6, (2105-2110), Online publication date: 1-Dec-2005.NADLER R, LOEB S, ROEHL K, ANTENOR J, EGGENER S and CATALONA W (2018) USE OF 2.6 NG/ML PROSTATE SPECIFIC ANTIGEN PROMPT FOR BIOPSY IN MEN OLDER THAN 60 YEARSJournal of Urology, VOL. 174, NO. 6, (2154-2157), Online publication date: 1-Dec-2005. Volume 172Issue 3September 2004Page: 910-914 Advertisement Copyright & Permissions© 2004 by American Urological Association, Inc.Keywordsprostatic neoplasmsprostatectomyprostateoutcome assessment (health care)MetricsAuthor Information KIMBERLY A. ROEHL More articles by this author MISOP HAN More articles by this author CHRISTIAN G. RAMOS More articles by this author JO ANN V. ANTENOR More articles by this author WILLIAM J. CATALONA More articles by this author Expand All Advertisement PDF downloadLoading ...